CNTX trades 1595.2% below Wall Street's consensus target of $5.25.
Last 12 months price action with 12-month analyst target path
The base valuation assumes CNTX achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 6 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of October 3, 2026, Context Therapeutics Inc. (CNTX) has a Wall Street consensus price target of $5.25, based on estimates from 6 covering analysts. With the stock currently trading at $0.31, this represents a potential upside of +1595.2%. The company has a market capitalization of $28M.
Analyst price targets range from a low of $4.50 to a high of $6.00, representing a 29% spread in expectations. The median target of $5.25 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 6 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, CNTX trades at a trailing P/E of -0.8x. Analysts expect EPS to grow +22.9% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 AGENAgenus Inc. | $348M | $8.36 | $25.00 | +199.0% | Buy | 31.3x | 11 |
 IMVTImmunovant, Inc. | $6.9B | $33.62 | $40.00 | +19.0% | Buy | — | 23 |
 ONCOOnconetix, Inc. | $3M | $0.72 | — | — | — | — | — |
 TPVGTriplePoint Venture Growth BDC Corp. | $199M | $4.90 | $5.00 | +2.0% | Hold | 5.5x | 12 |
 AGIOAgios Pharmaceuticals, Inc. | $1.9B | $31.80 | $42.67 | +34.2% | Buy | — | 29 |
 SNDXSyndax Pharmaceuticals, Inc. | $1.6B | $17.60 | $36.67 | +108.4% | Buy | — | 22 |
 RCUSArcus Biosciences, Inc. | $3.1B | $24.44 | $40.00 | +63.7% | Buy | — | 18 |
 PRMEPrime Medicine, Inc. | $538M | $2.98 | $7.50 | +151.7% | Buy | — | 10 |
 RVMDRevolution Medicines, Inc. | $43.9B | $206.64 | $252.35 | +22.1% | Buy | — | 24 |
 NUVLNuvalent, Inc. | $9.1B | $123.96 | $127.32 | +2.7% | Hold | — | 19 |
Quick answers to the most common questions about buying CNTX stock.
The consensus Wall Street price target for CNTX is $5.25, representing 1595.2% upside from the current price of $0.3097. With 6 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
CNTX has a consensus rating of "Buy" based on 6 Wall Street analysts. The rating breakdown is predominantly bullish, with 6 Buy/Strong Buy ratings. The consensus 12-month price target of $5.25 implies 1595.2% upside from current levels.
CNTX's current price is $0.3097 with a consensus target of $5.25 (1595.2% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $6 for CNTX, while the most conservative target is $4.5. The consensus of $5.25 represents the median expectation. These targets typically reflect 12-month expectations.
CNTX is moderately covered, with 6 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 6 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month CNTX stock forecast based on 6 Wall Street analysts shows a consensus price target of $5.25, with estimates ranging from $4.5 (bear case) to $6 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on CNTX, with a "Buy" consensus rating and $5.25 price target (1595.2% upside). 6 of 6 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
CNTX analyst price targets range from $4.5 to $6, a 29% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $5.25 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.